A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion

Richard J. Gumina, Tsuneo Mizumura, Norbert Beier, Pierre Schelling, Joel J. Schultz, Garrett J. Gross

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Administration of inhibitors of the Na+/H+ exchanger (NHE) have been shown to produce cardioprotective effects in a number of animal models of ischemia-reperfusion injury; however, controversy still exists as to the efficacy of these agents when administered just before reperfusion. To address this question, the efficacy of several doses of a new selective NHE- 1 isoform inhibitor (IC50 for inhibition of 22Na uptake in NHE-1 expressing mouse fibroblast cells = 10.4 ± 1.0 nM), EMD 85131 (2-methyl-5- methylsulfonyl-1 -(1-pyrrollyl)-benzoylguanidine), was tested in a canine infarct model in which the left anterior descending coronary artery was occluded for 60 min followed by 3 hr of reperfusion. EMD 85131 (0.75 or 3.0 mg/kg) was infused for 15 min before left anterior descending occlusion or 15 min before reperfusion. Infarct size was determined by use of the triphenyltetrazolium chloride histochemical stain and was expressed as a percent of the area at risk. EMD 85131 (0.75 or 3.0 mg/kg) administered before left anterior descending occlusion produced a marked (P < .05) and dose-related reduction in IS/AAR (24.3 ± 3.6%, control; 9.3 ± 3.4%, EMD 0.75; 6.4 ± 2.3%, EMD 3.0). These two doses of EMD also produced significant (P < .05) reductions in infarct size/area at risk (12.2 ± 2.1%, EMD 0.75; 13.0 ± 2.9%, EMD 3.0) when administered 15 min before reperfusion. These results suggest that selective NHE-1 inhibitors are able to markedly reduce infarct size when given before or during ischemia and also suggest that these compounds may have clinical utility when administered after the initiation of an ischemic insult.

Original languageEnglish (US)
Pages (from-to)175-188
Number of pages14
JournalJournal of Pharmacology and Experimental Therapeutics
Volume286
Issue number1
StatePublished - Jul 1 1998

Fingerprint

Sodium-Hydrogen Antiporter
Coronary Occlusion
Reperfusion
Hydrogen
Coronary Vessels
Sodium
Dogs
Reperfusion Injury
Inhibitory Concentration 50
Canidae
Protein Isoforms
Coloring Agents
Ischemia
Animal Models
Fibroblasts
hydrochloride N-diaminomethylene-2-methyl-5-methylsulfonyl-4-pyrrolobenzamide

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. / Gumina, Richard J.; Mizumura, Tsuneo; Beier, Norbert; Schelling, Pierre; Schultz, Joel J.; Gross, Garrett J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 286, No. 1, 01.07.1998, p. 175-188.

Research output: Contribution to journalArticle

Gumina, Richard J. ; Mizumura, Tsuneo ; Beier, Norbert ; Schelling, Pierre ; Schultz, Joel J. ; Gross, Garrett J. / A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. In: Journal of Pharmacology and Experimental Therapeutics. 1998 ; Vol. 286, No. 1. pp. 175-188.
@article{fde91a53ef2142c2909da60a8f0d69a6,
title = "A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion",
abstract = "Administration of inhibitors of the Na+/H+ exchanger (NHE) have been shown to produce cardioprotective effects in a number of animal models of ischemia-reperfusion injury; however, controversy still exists as to the efficacy of these agents when administered just before reperfusion. To address this question, the efficacy of several doses of a new selective NHE- 1 isoform inhibitor (IC50 for inhibition of 22Na uptake in NHE-1 expressing mouse fibroblast cells = 10.4 ± 1.0 nM), EMD 85131 (2-methyl-5- methylsulfonyl-1 -(1-pyrrollyl)-benzoylguanidine), was tested in a canine infarct model in which the left anterior descending coronary artery was occluded for 60 min followed by 3 hr of reperfusion. EMD 85131 (0.75 or 3.0 mg/kg) was infused for 15 min before left anterior descending occlusion or 15 min before reperfusion. Infarct size was determined by use of the triphenyltetrazolium chloride histochemical stain and was expressed as a percent of the area at risk. EMD 85131 (0.75 or 3.0 mg/kg) administered before left anterior descending occlusion produced a marked (P < .05) and dose-related reduction in IS/AAR (24.3 ± 3.6{\%}, control; 9.3 ± 3.4{\%}, EMD 0.75; 6.4 ± 2.3{\%}, EMD 3.0). These two doses of EMD also produced significant (P < .05) reductions in infarct size/area at risk (12.2 ± 2.1{\%}, EMD 0.75; 13.0 ± 2.9{\%}, EMD 3.0) when administered 15 min before reperfusion. These results suggest that selective NHE-1 inhibitors are able to markedly reduce infarct size when given before or during ischemia and also suggest that these compounds may have clinical utility when administered after the initiation of an ischemic insult.",
author = "Gumina, {Richard J.} and Tsuneo Mizumura and Norbert Beier and Pierre Schelling and Schultz, {Joel J.} and Gross, {Garrett J.}",
year = "1998",
month = "7",
day = "1",
language = "English (US)",
volume = "286",
pages = "175--188",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion

AU - Gumina, Richard J.

AU - Mizumura, Tsuneo

AU - Beier, Norbert

AU - Schelling, Pierre

AU - Schultz, Joel J.

AU - Gross, Garrett J.

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Administration of inhibitors of the Na+/H+ exchanger (NHE) have been shown to produce cardioprotective effects in a number of animal models of ischemia-reperfusion injury; however, controversy still exists as to the efficacy of these agents when administered just before reperfusion. To address this question, the efficacy of several doses of a new selective NHE- 1 isoform inhibitor (IC50 for inhibition of 22Na uptake in NHE-1 expressing mouse fibroblast cells = 10.4 ± 1.0 nM), EMD 85131 (2-methyl-5- methylsulfonyl-1 -(1-pyrrollyl)-benzoylguanidine), was tested in a canine infarct model in which the left anterior descending coronary artery was occluded for 60 min followed by 3 hr of reperfusion. EMD 85131 (0.75 or 3.0 mg/kg) was infused for 15 min before left anterior descending occlusion or 15 min before reperfusion. Infarct size was determined by use of the triphenyltetrazolium chloride histochemical stain and was expressed as a percent of the area at risk. EMD 85131 (0.75 or 3.0 mg/kg) administered before left anterior descending occlusion produced a marked (P < .05) and dose-related reduction in IS/AAR (24.3 ± 3.6%, control; 9.3 ± 3.4%, EMD 0.75; 6.4 ± 2.3%, EMD 3.0). These two doses of EMD also produced significant (P < .05) reductions in infarct size/area at risk (12.2 ± 2.1%, EMD 0.75; 13.0 ± 2.9%, EMD 3.0) when administered 15 min before reperfusion. These results suggest that selective NHE-1 inhibitors are able to markedly reduce infarct size when given before or during ischemia and also suggest that these compounds may have clinical utility when administered after the initiation of an ischemic insult.

AB - Administration of inhibitors of the Na+/H+ exchanger (NHE) have been shown to produce cardioprotective effects in a number of animal models of ischemia-reperfusion injury; however, controversy still exists as to the efficacy of these agents when administered just before reperfusion. To address this question, the efficacy of several doses of a new selective NHE- 1 isoform inhibitor (IC50 for inhibition of 22Na uptake in NHE-1 expressing mouse fibroblast cells = 10.4 ± 1.0 nM), EMD 85131 (2-methyl-5- methylsulfonyl-1 -(1-pyrrollyl)-benzoylguanidine), was tested in a canine infarct model in which the left anterior descending coronary artery was occluded for 60 min followed by 3 hr of reperfusion. EMD 85131 (0.75 or 3.0 mg/kg) was infused for 15 min before left anterior descending occlusion or 15 min before reperfusion. Infarct size was determined by use of the triphenyltetrazolium chloride histochemical stain and was expressed as a percent of the area at risk. EMD 85131 (0.75 or 3.0 mg/kg) administered before left anterior descending occlusion produced a marked (P < .05) and dose-related reduction in IS/AAR (24.3 ± 3.6%, control; 9.3 ± 3.4%, EMD 0.75; 6.4 ± 2.3%, EMD 3.0). These two doses of EMD also produced significant (P < .05) reductions in infarct size/area at risk (12.2 ± 2.1%, EMD 0.75; 13.0 ± 2.9%, EMD 3.0) when administered 15 min before reperfusion. These results suggest that selective NHE-1 inhibitors are able to markedly reduce infarct size when given before or during ischemia and also suggest that these compounds may have clinical utility when administered after the initiation of an ischemic insult.

UR - http://www.scopus.com/inward/record.url?scp=0031824640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031824640&partnerID=8YFLogxK

M3 - Article

C2 - 9655858

AN - SCOPUS:0031824640

VL - 286

SP - 175

EP - 188

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -